人福医药: 人福医药2025年半年度报告摘要

Core Viewpoint - Renfu Pharmaceutical Group Co., Ltd. reported a decrease in revenue for the first half of 2025, with total revenue of approximately 12.06 billion yuan, a decline of 6.20% compared to the same period last year [1]. Company Overview - The total assets of the company at the end of the reporting period were approximately 37.56 billion yuan, an increase of 2.87% from the previous year [1]. - The net assets attributable to shareholders of the listed company were approximately 18.34 billion yuan, reflecting a growth of 4.04% year-on-year [1]. - The net profit attributable to shareholders for the reporting period was approximately 1.15 billion yuan, an increase of 3.92% compared to the same period last year [1]. - The basic earnings per share for the reporting period were 0.71 yuan, up by 4.41% from 0.68 yuan in the previous year [1]. Shareholder Structure - As of the end of the reporting period, the total number of shareholders was 50,062 [1]. - The top ten shareholders collectively controlled 24.70% of the voting rights of the company [2]. - The new controlling shareholder is招商生科 (China Merchants Life Science), with the actual controller being招商局集团有限公司 (China Merchants Group) [3].